Renaissance Technologies
AUTL

Renaissance Technologies’s Autolus Therapeutics AUTL Stock Holding History

Renaissance Technologies’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Sell
1,984,700
-314,799
-14% -$494K ﹤0.01% 1706
2026
Q1 		$3.17M Sell
2,299,499
-805,905
-26% -$1.22M 0.01% 1635
2025
Q4 		$6.18M Sell
3,105,404
-1,775,968
-36% -$2.73M 0.01% 1190
2025
Q3 		$7.96M Buy
4,881,372
+3,130,172
+179% +$6.12M 0.01% 1204
2025
Q2 		$3.99M Buy
1,751,200
+167,075
+11% +$276K 0.01% 1661
2025
Q1 		$2.46M Buy
1,584,125
+965,183
+156% +$1.96M ﹤0.01% 1876
2024
Q4 		$1.45M Buy
618,942
+368,071
+147% +$1.24M ﹤0.01% 2264
2024
Q3 		$911K Sell
250,871
-894,185
-78% -$3.57M ﹤0.01% 2496
2024
Q2 		$3.98M Buy
1,145,056
+821,156
+254% +$3.54M 0.01% 1455
2024
Q1 		$2.07M Buy
323,900
+164,300
+103% +$1.02M ﹤0.01% 2012
2023
Q4 		$1.03M Sell
159,600
-114,079
-42% -$435K ﹤0.01% 2389
2023
Q3 		$638K Buy
273,679
+122,479
+81% +$349K ﹤0.01% 2601
2023
Q2 		$360K Buy
151,200
+42,800
+39% +$102K ﹤0.01% 3044
2023
Q1 		$199K Buy
108,400
+62,100
+134% +$121K ﹤0.01% 3284
2022
Q4 		$88K Buy
46,300
+21,100
+84% +$53.4K ﹤0.01% 3656
2022
Q3 		$54K Buy
25,200
+12,400
+97% +$36.7K ﹤0.01% 3738
2022
Q2 		$36K Buy
+12,800
New +$39K ﹤0.01% 4049
2021
Q2 		– Sell
-81,588
Closed -$467K – 3442
2021
Q1 		$467K Buy
81,588
+632
+0.8% +$4.68K ﹤0.01% 2931
2020
Q4 		$724K Buy
80,956
+27,300
+51% +$291K ﹤0.01% 2660
2020
Q3 		$625K Sell
53,656
-18,744
-26% -$272K ﹤0.01% 2742
2020
Q2 		$1.16M Sell
72,400
-88,096
-55% -$977K ﹤0.01% 2470
2020
Q1 		$961K Buy
160,496
+119,796
+294% +$1.11M ﹤0.01% 2445
2019
Q4 		$537K Sell
40,700
-8,300
-17% -$109K ﹤0.01% 2880
2019
Q3 		$609K Sell
49,000
-41,096
-46% -$543K ﹤0.01% 2797
2019
Q2 		$1.45M Buy
+90,096
New +$2.01M ﹤0.01% 2513

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Renaissance Technologies's AUTL Position: Q2 2026 in Review

Renaissance Technologies reduced its Autolus Therapeutics (AUTL) stake by 14% in Q2 2026, selling an estimated $494K and leaving 1,984,700 shares worth $3.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Renaissance Technologies first reported a position in AUTL in Q2 2019 and has held it in 25 quarters since. The position peaked at $7.96M in Q3 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Renaissance Technologies held 1,984,700 shares of Autolus Therapeutics worth $3.18M as of Q2 2026.
  • Renaissance Technologies sold 314,799 Autolus Therapeutics shares in Q2 2026, an estimated $494K.
  • Autolus Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1706 holding.
  • Renaissance Technologies first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Renaissance Technologies's Autolus Therapeutics position peaked at $7.96M in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.